Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1


Medical Devices

Pulmonx

Glendon E. French

Manu Joshi

Nick Pizzuti

Jon Biggs

Laure F.

Narinder Singh Shargill

Martin Schneider

Young Lee

Todd Galski

Tanner Johnson

Steve Wallace P.e.

Jim Outlaw

Jim Bobbitt

Conor McGuire

William Long

Marcee Maroney

Lisa Paul

Anna Gawlicka

David Lehman

Narinder S. Shargill

Mahtab Fatemi

Jérôme Erath

Sarah Huber

Kelly M. Shriner

Beran Rose

Sri Radhakrishnan

The Sales Team at Pulmonx is responsible for promoting and selling the Zephyr Endobronchial Valve to healthcare providers. They engage in relationship-building with pulmonologists, hospitals, and medical centers to drive product adoption and increase market share. Through education, training, and support, they aim to ensure successful implementation of the valve, ultimately helping improve the quality of life for patients with COPD/emphysema.

Sales Team

Leadership Team

Marketing

Sales Team

About

Team members

Other teams at Pulmonx

Leadership Team

Marketing